770718-92-8

Usage

Uses

Used in Synthetic Chemistry:
3-Bromo-5-Hydroxybenzonitrile is used as a building block for the synthesis of more complex chemical structures, particularly in the field of synthetic chemistry. Its unique arrangement of functional groups allows for versatile reactions and transformations, making it a valuable intermediate in the creation of a wide range of compounds.
Used in Pharmaceutical Industry:
3-Bromo-5-Hydroxybenzonitrile is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its presence in the molecular structure can contribute to the development of new drugs with potential therapeutic applications, such as in the treatment of diseases or conditions that require novel chemical entities.
Used in Material Science:
In the field of material science, 3-Bromo-5-Hydroxybenzonitrile is employed as a precursor in the development of new materials with specific properties. Its incorporation into the molecular structure of these materials can lead to the creation of advanced materials with applications in various industries, such as electronics, coatings, or adhesives.
Used in Research and Development:
3-Bromo-5-Hydroxybenzonitrile is utilized in research and development settings as a test compound for studying the effects of different functional groups on the properties and reactivity of chemical structures. This can lead to a better understanding of chemical behavior and the discovery of new synthetic pathways or methods.

Upstream product

• 262450-65-7 3-bromo-5-methoxybenzaldehyde 
• 157893-14-6 3-bromo-5-methoxybenzoic acid 
• 262450-64-6 (3-bromo-5-methoxyphenyl)methanol 
• 867366-91-4 3-bromo-5-methoxybenzonitrile 

Downstream Products

• 770718-93-9 [3-(3-bromo-5-cyano-phenoxy)-2-fluoro-4-nitro-phenyl]-acetic acid ethyl ester 

Relevant academic research and scientific papers

NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Compound of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y and G are as defined in the description, and their use in the manufacture of medicaments.

NOVEL NON-SYSTEMIC TGR5 AGONISTS

The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Compounds of formula I, wherein R1, R2, R3, X1, X2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, X1 and X2 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A1, A2, A3 or A4 and R1, R2, R3, R4a, R4b, R5, R6, Ar, X1, X2, X4, X4 and X5 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

Non-nucleoside reverse transcriptase inhibitors

Compounds of formula I, wherein R1, R2, R3, R4, Ra, X, X1, and Y are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Non-nucleoside reverse transcriptase inhibitors

Compounds of formula I, wherein R1, R2, R3, R4, R5, X, Y, and Ar are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to formula I where Ar, R1-R5, R7a, R7b, R7c, R8-R10, X1, X2 m, n, o and p are as defined herein.

Non-nucleoside reverse transcriptase inhibitors

This invention relates to novel pyridazinone derivatives of formula I wherein R1-R4, R7, R8 and X1 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I, pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient and processes to prepare compounds of formula I. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated